Denmark plans to thwart deepfakers by giving everyone copyright over their own features
The Danish government is planning to tackle the issue of AI-generated deepfakes by granting citizens property rights over their likeness and voice.
The proposed legislation would mean that people who find that their features have been used to create a deepfake would have the right to ask the platforms that host the content to take it down, Danish Culture Minister Jakob Engel-Schmidt told CNN on Friday.
Engel-Schmidt believes that 'technology has outpaced legislation' and the proposed law would help to protect artists, public figures and ordinary people from digital identity theft, which he said is now possible with just a few clicks thanks to the power of generative AI.
'I think we should not accept a situation where human beings can be run through, if you would have it, a digital copy machine and misused for all sorts of purposes,' he said.
He cited the example of musical artists who have discovered songs online purporting to be theirs, but which have in fact been made using AI clones of their voice.
One such case involves Canadian singer Celine Dion, who in March warned fans about AI-generated content featuring her voice and likeness that was circulating online.
And in April 2024, more than 200 artists, including Billie Eilish, Kacey Musgraves, J Balvin, Ja Rule, Jon Bon Jovi, the Jonas Brothers, Katy Perry and Miranda Lambert, signed an open letter speaking out against AI-related threats in the music industry.
Engel-Schmidt says he has secured cross-party support for the bill, and he believes it will be passed this fall.
Once the legislation is passed, Engel-Schmidt believes a second step would be to introduce more legislation that could impose fines on companies that do not comply with requests to remove content featuring an AI-generated deepfake.
'We are champions of freedom of speech, we would like everyone to be heard, but we also believe that human beings have the right to say yes and no to them being used by generative AI,' he said.
As for whether he has discussed the proposed legislation with tech companies, Engel-Schmidt said: 'Not yet, but I'm looking forward to it. I think it's in their interest as well to make AI work for humanity, not against, you know, artists, popular figures and ordinary people.'
Athina Karatzogianni, a professor of technology and society at the University of Leicester, England, told CNN that the Danish proposal is one of hundreds of policy initiatives around the world looking to reduce the possible harms associated with the misuse of generative AI.
'Deepfakes can have both individual and social impact, because they can both harm individual rights and also (have) sociopolitical impacts, because they undermine the values that are fundamental to a democracy, such as equality and transparency,' said Karatzogianni.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
34 minutes ago
- Yahoo
10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential
The healthcare sector offers an abundance of high-growth investment opportunities. Companies leveraging artificial intelligence and genomic medicine are delivering innovative therapies with significant potential. Small-cap and under-the-radar stocks with strong growth possibilities merit closer investor attention. 10 stocks we like better than TransMedics Group › There's a strong case that healthcare is the most important sector in the stock market. These companies deliver innovative therapies and medical technologies that are often life-saving. Investors stand to benefit as healthcare leaders and emerging players address the needs of an aging global population and the rising prevalence of chronic diseases. Here are 10 under-the-radar healthcare stocks that could be great buys for your portfolio. Certara (NASDAQ: CERT) is poised to capitalize on the transformation in medicine driven by artificial intelligence (AI), providing bio-simulation software and services that accelerate drug development. The company plays a crucial role in the pharmaceutical industry. Over 90% of all novel drugs approved by the Food and Drug Administration (FDA) since 2014 have leveraged its technology. Its AI-driven solutions enhance research and development (R&D), enabling faster and more precise drug development. Certara deserves a closer look by investors seeking to tap into the AI-driven healthcare transformation. Beam Therapeutics (NASDAQ: BEAM) is a clinical-stage biotech pioneering precision-based gene editing therapies for genetic diseases, including sickle cell disease. Its innovative technology enables precise single-nucleotide DNA changes, potentially offering a safer alternative to traditional CRISPR genetic engineering. Beam has reported early success in gene correction, with its lead candidate, BEAM-101, in phase 1/2 trials for sickle cell disease. While the company still has a lot to prove, its differentiated approach and clinical progress position it for remarkable growth in the long term. Inspire Medical Systems (NYSE: INSP) develops implantable neurostimulation devices for obstructive sleep apnea, offering its FDA-approved Inspire therapy as a noninvasive alternative to CPAP machines. In its first quarter (the period ended March 31), revenue surged 23% year over year to $201 million, driven by growing U.S. adoption and new international approvals. With increasing demand for sleep apnea treatment, Inspire has a significant opportunity to capture market share. Insulet (NASDAQ: PODD) specializes in tubeless insulin pump technology. Its Omnipod system simplifies diabetes management for Type 1 and insulin-dependent Type 2 patients globally, offering convenience and improved outcomes. With a 2025 revenue growth target of 19% to 22%, the company is poised for continued expansion, particularly in underpenetrated international markets. Insulet's strong growth trajectory positions it to reward shareholders further. Krystal Biotech (NASDAQ: KRYS) focuses on rare skin diseases. Its FDA-approved gene therapy, Vyjuvek, for dystrophic epidermolysis bullosa (fragile skin that blisters easily) is expected to approach $400 million in revenue this year, solidifying its position as a best-in-class treatment. Vyjuvek's success validates Krystal's R&D, bolstering confidence in its pipeline and unlocking added market potential. LifeMD (NASDAQ: LFMD) operates a telehealth platform providing specialized virtual care in weight loss, men's health, and dermatology. A partnership with Novo Nordisk to offer Wegovy, a leading GLP-1 treatment, has driven impressive growth, with first-quarter revenue surging 49% year over year for the period ended March 31. LifeMD could expand its growing user base into a comprehensive health management ecosystem to fuel growth and solidify its telehealth leadership. Option Care Health (NASDAQ: OPCH) is the leading U.S. provider of home and alternative-site infusion services, delivering crucial therapies for chronic and acute conditions like cancer, immune deficiencies, and infections. As the healthcare industry shifts toward more personalized and cost-effective care, Option Care Health is in position to capitalize on the strong demand, with its extensive network and high-quality services. Tempus AI (NASDAQ: TEM) harnesses artificial intelligence to advance precision medicine, using its collection of clinical and molecular data from more than 40 million patients to power diagnostics in oncology, cardiology, and beyond. The company projects its revenue to climb by more than 80% this year, to about $1.3 billion. Tempus AI's scalable platform and extensive data ecosystem present substantial opportunities for expansion and impact in personalized healthcare. TransMedics Group (NASDAQ: TMDX) has revolutionized organ transplantation with its Organ Care System (OCS), the only FDA-approved device for heart, lung, and liver transplants that extends organ preservation time. The company's projected revenue growth of 30% this year underscores the strong momentum in a global expansion opportunity. Veeva Systems (NYSE: VEEV) offers cloud-based software that streamlines clinical, regulatory, and commercial processes for life sciences companies. Serving over 1,000 customers, including major pharmaceutical companies and emerging biotechs, Veeva's platform is well positioned to capitalize on the industry's increasing reliance on digital solutions for innovation and compliance. Before you buy stock in TransMedics Group, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and TransMedics Group wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $713,547!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $966,931!* Now, it's worth noting Stock Advisor's total average return is 1,062% — a market-crushing outperformance compared to 177% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 23, 2025 Dan Victor has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Beam Therapeutics, Inspire Medical Systems, TransMedics Group, and Veeva Systems. The Motley Fool recommends Insulet, Krystal Biotech, and Novo Nordisk. The Motley Fool has a disclosure policy. 10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential was originally published by The Motley Fool
Forbes
43 minutes ago
- Forbes
Billie Eilish's Single Reaches New Peaks, A Year Into Its Life On The Charts
Billie Eilish's 'Wildflower' reaches new highs on the Pop Airplay and Radio Songs charts after more ... More than a year on several of Billboard's rock and alternative rankings. STOCKHOLM, SWEDEN - APRIL 23: Billie Eilish performs at Avicii Arena on April 23, 2025 in Stockholm, Sweden. (Photo by Samir Hussein/WireImage for Live Nation) Billie Eilish's current single 'Wildflower' will likely serve as the final promotional cut from her album Hit Me Hard and Soft. The track has already spent more than a year appearing on a number of Billboard charts, as it has been a fan favorite ever since its parent release arrived, and only in the past few months has it finally earned the promotional push it has long deserved. After a year on multiple rankings, 'Wildflower' is still relatively new to some other tallies, and it is hitting new peaks on several lists at the same time. 'Wildflower' Almost Reaches the Top 10 'Wildflower' has only spent a few weeks on some of Billboard's radio rankings, as it was only sent to stations months ago. This week, the track hits a new high point on all three of the radio rosters on which it currently appears. The cut is inching closer to the top 10 on the Pop Airplay tally, where this frame it ascends to No. 12. Over on the Adult Pop Airplay list, Eilish's cut reenters at No. 35, which now stands as its best showing. The same tune pushes three spots north on the all-genre Radio Songs ranking and settles in the same position as on the Adult Pop Airplay tally. Only a Few Weeks on the Radio Charts 'Wildflower' has spent 15 weeks on the Pop Airplay chart, the most among the radio rosters. It has only racked up six frames on the Radio Songs tally and five weeks, including this comeback, on the Adult Pop Airplay ranking. 'Wildflower' Has Lived on the Rock Lists for a Year Meanwhile, when looking at Billboard's rock and alternative lists — those which are not focused entirely on airplay — 'Wildflower' has been a mainstay for over a year. Eilish's smash has spent 57 weeks on all of the following rankings: the Hot Rock & Alternative Songs, Hot Rock Songs, Hot Alternative Songs, Rock Streaming Songs, and Alternative Streaming Songs charts. It also reached its first year on the Hot 100 just last week.
Yahoo
44 minutes ago
- Yahoo
If I Could Only Buy 1 Artificial Intelligence (AI) Stock, It Would Be This Monster "Magnificent Seven" Member Approved by Billionaires Warren Buffett and Bill Ackman
Earlier this year, Bill Ackman bought a megacap AI stock -- joining Warren Buffett as a high-profile shareholder. Ackman and Buffett are both value investors, making the timing of Ackman's purchase particularly brilliant. While the markets have been moving higher over the last several weeks, Amazon remains my top pick. 10 stocks we like better than Amazon › Bill Ackman is a billionaire investor and serves as CEO to the hedge fund Pershing Square Capital Management. Throughout the artificial intelligence (AI) revolution, Pershing Square's primary exposure to the stock market's latest megatrend has been through a position in Alphabet. Recently, however, Ackman made headlines after it was revealed that Pershing Square complemented its Alphabet position with another member of the "Magnificent Seven": Amazon (NASDAQ: AMZN). Interestingly, Amazon is one of the few technology stocks featured in Warren Buffett's portfolio at Berkshire Hathaway. Let's explore why billionaire investors like Buffett and Ackman may have taken a liking to Amazon. Moreover, I'll break down why the e-commerce and cloud computing giant is my top pick among AI stocks. Ackman and Buffett built their fortunes in different ways. Buffett is best known for building positions in globally recognized brands and holding onto these stocks over the course of many years or even decades. In addition, many of Buffett's most lucrative investments have come from companies that consistently buy back stock or pay a dividend. Lastly, Buffett generally sticks to industries such as financial services, energy, and consumer goods -- rarely exposing Berkshire to more volatile markets such as the technology sector. On the other hand, Ackman tends to be a bit more industry-agnostic compared to Buffett. Moreover, from time to time Ackman will also profit from more sophisticated trading techniques that involve derivatives. One philosophy that Buffett and Ackman do share, however, is their love for value stocks. Neither investor is known for chasing momentum or overpaying for a stock trading with a lofty valuation. The chart above benchmarks Amazon's price action relative to other megacap AI and cloud computing stocks. While each stock above faced some pressure earlier this year, Amazon's decline was more pronounced relative to its peers -- specifically throughout April. This is when Ackman pounced, buying the dip in Amazon stock during a period of notable valuation contraction. Furthermore, I think Amazon's diversified ecosystem spanning online shopping, cloud computing, subscription services, logistics, robotics, grocery delivery, streaming and entertainment, and more is another factor that played a role in the tech giant earning a spot in both Berkshire's and Pershing Square's portfolios. By operating across so many different end markets, Amazon is able to thrive under various economic conditions while also appealing to several different customer demographics. Buffett and Ackman may favor business models like this as it helps mitigate risk factors such as cyclicality, seasonality, and growth unpredictability. Given the ideas explored above, Amazon may not appear to be a traditional AI opportunity. But over the last few years, Amazon has quietly been transforming its business through a series of AI-driven investments. For starters, the company invested $8 billion into a start-up called Anthropic. Anthropic has become a key integration in Amazon Web Services (AWS), leading to sustained acceleration across revenue and profitability in the company's cloud computing business. Amazon is also deploying AI robotics throughout its fulfillment centers. This move has the potential to generate significant cost savings by bringing new levels of automation and efficiency to the company's warehouses. Moreover, while companies like IonQ or Rigetti Computing fetch the majority of attention in the quantum computing arena, Amazon is developing its own line of chipsets: Trainium, Inferentia, and Ocelot. Based on forward earnings multiples, Amazon stock isn't exactly a bargain right now. My hunch is that Amazon's diverse business and robust growth prospects may make the company appear to be more of a safe haven relative to other volatile, unpredictable opportunities in the AI realm. Even so, I don't think Amazon has experienced the same level of valuation expansion that some of its Magnificent Seven peers (e.g., Microsoft, Nvidia) have over the last couple of years. Furthermore, given how many different businesses AI stands to disrupt within the Amazon ecosystem, I think the company is uniquely positioned for sustained periods of robust growth. With that in mind, I think Amazon still has significant upside and I see a position in the stock as a superior opportunity compared to its peers. Investors with a long-run time horizon may want to consider initiating a position in Amazon stock despite its slight premium right now. Before you buy stock in Amazon, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Amazon wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $713,547!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $966,931!* Now, it's worth noting Stock Advisor's total average return is 1,062% — a market-crushing outperformance compared to 177% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 23, 2025 Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Adam Spatacco has positions in Alphabet, Amazon, Microsoft, and Nvidia. The Motley Fool has positions in and recommends Alphabet, Amazon, Berkshire Hathaway, Microsoft, Nvidia, and Oracle. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy. If I Could Only Buy 1 Artificial Intelligence (AI) Stock, It Would Be This Monster "Magnificent Seven" Member Approved by Billionaires Warren Buffett and Bill Ackman was originally published by The Motley Fool
